US Marshals Seize Tri-Med Drugs After Several GMP Warnings

U.S. marshals seized OTC and prescription drugs from Tri-Med Laboratories at the FDA’s request because the products were unapproved and manufactured in violation of GMPs.

The Somerset, N.J., facility had refused to take the products off the market despite several warning letters and regulatory meetings with the agency, Dara Corrigan, FDA associate commissioner for regulatory affairs, said.

Inspections of Tri-Med since 1997 show the company continued to manufacture and distribute unapproved, misbranded and adulterated drugs with significant GMP violations.
Drug GMP Report